Meg Jardine

Jun 13, 2023 | drc.bmj.com | David M. Charytan |Kenneth W. Mahaffey |Meg Jardine |Christopher Cannon

DiscussionIn this post hoc analysis of the CREDENCE study, we demonstrated that the glycemic effects of canagliflozin were modified by baseline eGFR, with a progressively lesser reduction and lower likelihood of achieving a >0.5% decrease in HbA1c across CKD stages G1-2 (eGFR >60 mL/min/1.73 m2), stage G3A (eGFR 45–60 mL/min/1.73 m2), and stage 3B (eGFR 30–44 mL/min/1.73 m2).